



REEDFAX Document Delivery System
A service of Reed Technology and Information Services, Inc.
275 Gibraltar Road, Horsham, PA 19044-0962
Phone: 1 800-422-1337 or 215-441-4768
FAX: 1 800-421-5585 or 215-441-5463

REEDFAX - The Patent Connection (R)
Automated Patent and Trademark Delivery System

300 dots per inch Laser Printed Document

Company Number: 2134
Account Number: 213445
Client Reference: 0001539

Date: 12/22/2003
Time: 11:46:42 AM

Control Number: 79871

Document Number: WO0192263A1
Pages: 29

Description: WO-Prt-Mail-Sys
Request Number: 1

CHARGES FOR THIS DOCUMENT: Discount D5

Basic Charge:	\$	11.50
Extra Pages:	\$	0.00
Special Serv:	\$	0.00
Surcharge:	\$	0.00

Total Charge: \$ 11.50

CHARGES LISTED ARE FOR INFORMATIONAL PURPOSES ONLY
DOES NOT INCLUDE APPLICABLE TAX OR OTHER ADJUSTMENT
*****< THIS IS NOT A BILL >*****

**(19) World Intellectual Property Organization
International Bureau**



(43) International Publication Date
6 December 2001 (06.12.2001)

PCT

(10) International Publication Number
WO 01/92263 A1

(51) International Patent Classification⁷: C07D 487/04

(74) Agent: GLOBAL INTELLECTUAL PROPERTY; AstraZeneca AB, S-151 85 Södertälje (SE).

(21) International Application Number: PCT/SE01/01241

(22) International Filing Date: 31 May 2001 (31.05.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0013488.2	2 June 2000 (02.06.2000)	GB
0002102-2	6 June 2000 (06.06.2000)	SE

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (for all designated States except US): AS-TRAZENECA AB [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and


(75) **Inventors/Applicants (for US only):** **LARSSON, Ulf** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **MAGNUSSON, Mattias** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE). **MUSIL, Tibor** [SE/SE]; AstraZeneca Bulk Production, S-151 85 Södertälje (SE). **PALMGREN, Andreas** [SE/SE]; AstraZeneca R & D Södertälje, S-151 85 Södertälje (SE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL TRIAZOLO PYRIMIDINE COMPOUNDS




(57) Abstract: The present invention relates to a pyrimidine compound (I) useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.

WO 01/92263 A1


NOVEL TRIAZOLO PYRIMIDINE COMPOUNDS

The present invention relates to a pyrimidine compound useful as a pharmaceutical intermediate, to a process for preparing said pyrimidine compound, to intermediates used
5 in said process, and to the use of said pyrimidine compound in the preparation of pharmaceuticals.


The present invention provides a compound of formula (I):



The present invention also provides a process for preparing a compound of formula
10 (I), comprising reacting a compound of formula (II):




with a salt of a compound of formula (III):



in the presence of a suitable base (such as an alkali metal hydroxide (such as sodium or
15 potassium hydroxide) a tertiary amine (such as a tri(C₁₋₆ alkyl)amine, for example triethylamine)), a suitable solvent (such as an alcohol, such as an aliphatic alcohol containing from 1 to 6 carbon atoms, for example ethanol), preferably at a temperature in the range 100-150°C and, where necessary (for example when the temperature exceeds the boiling point of the solvent), in a sealed system under autogenic pressure.

A suitable salt of a compound of formula (III) is a salt of a mineral or organic acid. Suitable mineral acids include hydrochloric, hydrobromic, hydroiodic, nitric or sulphuric acid. A suitable organic acid is, for example, an organic achiral acid such as acetic, trifluoroacetic, oxalic or p-toluenesulphonic acid, or an organic chiral acid such as L-
 5 tartaric acid, dibenzoyl-L-tartaric acid or di-p-toluoyl-L-tartaric acid.


In another aspect the present invention provides a process for preparing a compound of formula (I) comprising hydrogenating a compound of formula (IV):



wherein Ar is phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy; to give a
 10 compound of formula (II), and reacting the compound of formula (II) with a compound of formula (III) (as described above) to provide the compound of formula (I).

The hydrogenation is preferably conducted using a heavy metal catalyst (such as platinum on carbon), in a suitable solvent (such as a C₁₋₆ aliphatic alcohol, for example 2-propanol (*iso*-propanol)), at a suitable temperature (such as 10-70°C, for example 20-50°C)
 15 and at a suitable pressure (such as 1-5 bar, for example about 3 bar).


A compound of formula (IV) can be prepared by chlorinating a compound of formula (VIII):



wherein Ar is as defined above, with a suitable chlorinating agent (such as phosphorus
 20 oxychloride) in the presence of a suitable nitrogen containing base (such as triethylamine, especially pyridine) and at a suitable temperature (such as in the range 50°C to the boiling point of phosphorus oxychloride; for example 70 to 90°C). A compound of formula (VIII) can be prepared by routine adaptation of literature methods.


In a further aspect the present invention provides a process, as hereinbefore
 25 described, for the preparation of a compound of formula (II).

The compound of formula (I) can be used to prepare the pharmaceutical compound of formula (A):




as described below.

5 Thus, a compound of formula (A) can be prepared by deprotecting a compound of formula (V):




for example using a strong mineral acid (such as hydrochloric acid) in a suitable solvent (such as methanol or ethanol).

10 A compound of formula (V) can be prepared by coupling a compound of formula (VI) {or a salt thereof (such as a mandelate salt) from which the compound of formula (VI) is generated *in situ*}, with a compound of formula (VII):



(VI)



(VII)


for example in the presence of a suitable base (such as a tertiary amine, such as a tri(C₁₋₆ alkyl)amine, for example triethylamine) and a suitable solvent (for example a polar solvent, such as an alcohol (such as an aliphatic alcohol containing from 1 to 6 carbon atoms, for example ethanol) or a nitrile (such as acetonitrile)) and at a suitable temperature (such as a temperature in the range 10-40°C, for example ambient temperature).

A compound of formula (VII) can be prepared by reacting a compound of formula (I) with an alkali metal nitrite (such as NaNO₂) or an organic nitrite (for example *iso*-amyl nitrite) in the presence of a suitable acid (such as acetic acid) and a suitable solvent (such as water or a mixture of water and acetic acid) and at a suitable temperature (such as a temperature in the range -10 to 15°C, for example -10 to 10°C).

Thus, in a further aspect the present invention provides the use of the compound of formula (I) in a process for the preparation of the compound of formula (A).

A salt of a compound of formula (III) can be prepared by reacting a compound of formula (III) with the necessary acid in a suitable solvent (such as water, an aliphatic alcohol containing 1 to 4 carbon atoms (for example ethanol) or a simple ester (such as ethyl acetate)) at a suitable temperature (such as from 10 to 60°C, for example 30 to 50°C).

A compound of formula (III) can be prepared by deprotecting a compound of formula (IX):




(IX)

for example by hydrogenation {such as with a heavy metal catalyst (such as palladium on carbon) in the presence of a solvent (such as an aliphatic alcohol containing 1 to 4 carbon


atoms, for example ethanol) at ambient temperature at a suitable pressure (such as 1 to 3 bar, for example 1.0 to 1.5 bar)).

A compound of formula (IX) can be prepared by reducing a compound of formula (X):




wherein R* is C₁₋₄ alkyl (preferably ethyl), such as with a suitable borohydride (for example an alkali metal borohydride, such as lithium borohydride), lithium aluminiumhydride or DIBAL-H in a suitable polar solvent (such as tetrahydrofuran).

A compound of formula (X) can be prepared by reacting a compound of formula (XI):



with a suitable compound L-CH₂CO₂R* {wherein R* is C₁₋₄ alkyl (especially ethyl); and L is a leaving group, especially halogen (for example bromo)}, in the presence of a suitable polar solvent (such as tetrahydrofuran) and in the presence of a suitable base (such as potassium tert-butoxide, sodium hydride or a C₁₋₆ alkyl lithium species).

A compound of formula (XI) can be prepared by reacting a compound of formula (XII):



with benzyl chloroformate in the presence of a suitable base (such as potassium carbonate) and a suitable solvent (such as a ketone (for example 4-methyl-2-pentanone) or a hydrocarbon (for example toluene)).

In a still further aspect the present invention provides a process for the preparation of a salt of a compound of formula (III) as hereinbefore described.

In further aspects the present invention provides an intermediate compound of formulae (II), (IV), (VII), (VIII), (X) or (XI), or a salt of a compound of formula (III).

The following Examples illustrate the invention.

EXAMPLE 1

This Example illustrates the preparation of 2-([(3*aR*,4*S*,6*R*,6*aS*)-6-amino-2,2-dimethyltetrahydro-3*aH*-cyclopenta[*d*][1,3]-dioxol-4-yl]oxy)-1-ethanol, L-tartaric acid salt (1:1).

10 Step a: Preparation of [3*aS*-(3*aα*,4*α*,6*α*,6*aα*)]-[tetrahydro-6-hydroxy-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester.

Potassium carbonate (39.3g) was added to a suspension of [3*aR*-(3*aα*,4*α*,6*α*,6*aα*)]-6-amino-tetrahydro-2,2-dimethyl-4*H*-cyclopenta-1,3-dioxol-4-ol, hydrochloride, (prepared as described in WO 9905142) (27.1g) in 4-methyl-2-pentanone (500ml). Water (150ml)
15 was then added followed by dropwise addition of benzyl chloroformate (23.1g). The reaction mixture was stirred at room temperature for 4 hours before the organic phase was separated. The aqueous phase was extracted with 4-methyl-2-pentanone (2x50ml). The combined organics were concentrated and the residue was purified (SiO₂, dichloromethane:methanol, 95:5 to 90:10 as eluant) to give the subtitle compound
20 (39.23g).

¹H NMR (CDCl₃) δ 7.32 (5H, m), 5.65 (1H, br s), 5.10 (2H, br s), 4.59 (1H, d), 4.48 (1H, d), 4.27 (1H, m), 4.19 (1H, br m), 2.24 (1H, br s), 1.69 (1H, d), 1.41 (3H, s), 1.26 (3H, s).

25 Step b: Preparation of [3*aS*-(3*aα*,4*α*,6*α*,6*aα*)]-[2,2-dimethyl-6-(2-hydroxyethoxy)-tetrahydro-4*H*-cyclopenta-1,3-dioxol-4-yl]-carbamic acid, phenylmethyl ester.

Potassium tert-butoxide (3.6g) in tetrahydrofuran (20ml) was added over 5 minutes to a solution of the product from Step (a) (39.23g) in tetrahydrofuran (200ml). After 15 minutes, ethyl bromoacetate (3.7ml) in tetrahydrofuran (10ml) was added dropwise. The
30 mixture was stirred at 0°C for 10 minutes, then further ethyl bromoacetate was added (3.7ml x4). The reaction mixture was stirred at 0°C a further 2 hours.

Lithium borohydride (2.79g) was then added portionwise to the reaction mixture which was then stirred at <5°C for 16 hours. Glacial acetic acid (23g) was added dropwise to the cold mixture. After stirring for 30 minutes, water (100ml) was added dropwise and the resulting mixture was stirred for 30 minutes. The phases were then separated and the aqueous phase was extracted with ethyl acetate. The combined organics were washed with saturated sodium bicarbonate and brine, dried and concentrated. The residue was purified (SiO₂, ethyl acetate:hexane, 25:75 to 50:50 as eluant) to give the subtitle compound (38.6g).

MS (APCI) 218 (M+H⁺, 100%).

Step c: Preparation of [3aR-(3a α ,4 α ,6 α ,6a α)]-2-[[6-amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol (alternatively named: 2-[[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-yl]oxy}-1-ethanol).

A slurry of 5% palladium on charcoal (4g) in ethanol was added to a solution of the product from Step (b) (39.96g) in ethanol (250ml) and the mixture was hydrogenated at 1.2 bar for 20 hours. The catalyst was filtered off and the filtrate was concentrated to give the subtitle compound (23.65g).

MS (APCI) 160 (M+H⁺, 100%).

Step d: Preparation of [3aR-(3a α ,4 α ,6 α ,6a α)]-2-[[6-amino-2,2-dimethyl-tetrahydro-4H-cyclopenta-1,3-dioxol-4-yl]oxy]-ethanol L tartrate (alternatively named: 2-[[[(3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]-dioxol-4-yl]oxy}-1-ethanol, L-tartaric acid salt (1:1)).

A stirred solution of the product obtained in Step (c) (545g) in ethanol (3.8l) was heated to 35°C. L-tartaric acid (352g) was added (temperature rise to 45°C) and the mixture was stirred at 40 - 45°C for 1 h. The mixture was cooled to 20°C and the resulting thick slurry stirred for 16 h then filtered. The collected solid was washed with two portions of 2-propanol (300ml, then 500ml), sucked dry then dried *in vacuo* at 40°C to give the product as white crystals (728g).

EXAMPLE 2

This Example illustrates the preparation of *trans*-(1*R*,2*S*)-2-(3,4-difluorophenyl)-cyclopropylamine, R-mandate salt (alternatively named *trans*-(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropanaminium (2*R*)-2-hydroxy-2-phenylethanoate.

5 Step 1: Preparation of (*E*)-3-(3,4-difluorophenyl)-2-propenoic acid.

A stirred mixture of pyridine (15.5kg) and piperidine (0.72kg) were heated to 90°C. Malonic acid (17.6kg) was added, followed by slow addition, over 50 minutes, of 3,4-difluorobenzaldehyde (12.0kg). The reaction mixture was stirred at 90°C for a further 4 hours and 36 minutes. Water (58.5kg) was added and 32 litres of the pyridine/water
10 mixture then was distilled out of the reactor under reduced pressure. The reaction mixture was acidified to pH 1 with 37% hydrochloric acid (6.4kg) over a 40 minute period, then cooled to 25°C with strong stirring. The solids were collected by filtration, washed twice with 1% hydrochloric acid (34.8 L per wash), once with water (61 L) and then deliquored thoroughly in the filter. The product was then dried under vacuum at 40°C for 24 hours and
15 40 minutes, affording 13.7kg of the crystalline product.

Step 2: Preparation of (*E*)-3-(3,4-difluorophenyl)-2-propenoyl chloride.

A stirred mixture of (*E*)-3-(3,4-difluorophenyl)-2-propenoic acid (8.2 kg), toluene (7.4kg) and pyridine (0.18kg) was heated to 65°C and then thionyl chloride (7.4kg) was
20 added over 30 minutes. The reaction was stirred for a further 2h 15 minutes after the addition was complete, then diluted with toluene (8.7kg). Excess thionyl chloride, sulfur dioxide and hydrogen chloride were then distilled out, together with toluene (10 L), under reduced pressure, yielding a solution of the (*E*)-3-(3,4-difluorophenyl)-2-propenoyl chloride (approximately 9kg) in toluene.

25

Step 3: Preparation of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl (*E*)-3-(3,4-difluorophenyl)-2-propenoate.

A solution of *L*-menthol (7.1kg) in toluene (8.5kg) was added over a 20 minute period to the solution of (*E*)-3-(3,4-difluorophenyl)-2-propenoyl chloride (prepared as in
30 Step 2) and pyridine (0.18kg, 2.28 mol) stirring at 65°C. The reaction mixture was stirred at 65°C for a further 4 hours and 40 minutes after the addition was complete, then cooled

to 25°C and stirred for a 14 hours. The solution was diluted with toluene (16kg), washed with 5% aqueous sodium chloride (6.4kg), then 6% sodium hydrogen carbonate (6.47kg), then water (6.1kg). The solution was dried azeotropically by distillation of the solvent (20 L) under reduced pressure. Dimethyl sulfoxide (33.9kg) was added and the remaining
5 toluene was distilled off under reduced pressure, affording 47.3kg of a solution of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl (*E*)-3-(3,4-difluorophenyl)-2-propenoate (approx. 13.3kg) in dimethyl sulfoxide.

Step 4: Preparation of dimethylsulfoxonium methylide (dimethyl(methylene)oxo- λ^6 -
10 sulfane.

Sodium hydroxide powder (1.2kg), prepared by milling sodium hydroxide pellets in a rotary mill through a 1mm metal sieve, and trimethylsulfoxonium iodide (6.2kg) were stirred in dimethyl sulfoxide (25.2kg) under a nitrogen atmosphere at 25°C for 90 min. The solution was used directly in the preparation of (1*R*, 2*S*, 5*R*)-2-isopropyl-5-
15 methylcyclohexyl *trans*-2-(3,4-difluorophenyl)cyclopropanecarboxylate.

Step 5: Preparation of (1*R*, 2*S*, 5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-2-(3,4-difluorophenyl)cyclopropanecarboxylate.

A solution of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl (*E*)-3-(3,4-difluorophenyl)-2-propenoate (approximately 8.6kg) in dimethyl sulfoxide (approximately 27.9kg) was added with stirring over 20 minutes to a mixture of dimethylsulfoxonium methylide (approximately 2.6kg, prepared as described above), sodium iodide (approximately 4.2kg), water (approximately 500g) and sodium hydroxide (approximately 56g) in dimethylsulfoxide(27.7kg) at 25°C. The reaction mixture was stirred for a further 2
25 hours and 50 minutes at 25°C, then used directly for the preparation of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-(1*R*,2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylate.

Step 6: Preparation of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-(1*R*,2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylate
30

A crude solution of (1*R*, 2*S*, 5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-2-(3,4-difluorophenyl)cyclopropanecarboxylate produced as described in step 5 was heated with

stirring from 25°C to 50°C over a 1 hour period and the temperature was maintained for a further hour. The mixture was then cooled with stirring from 50°C to 35°C over 4 hours, kept at 35°C for 1 hour, then cooled to 26°C over 4 hours, kept at 26°C for 1 hour, then cooled to 19°C over 3 hours and kept at 19°C for 5 hours and 10 minutes. The product was collected by filtration, affording a crystalline solid (2.7kg) which was shown to contain a mixture of (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-(1*R*,2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylate (1.99 kg) and (1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-(1*S*,2*S*)-2-(3,4-difluorophenyl)cyclopropanecarboxylate (85g).

10 Step 7: Preparation of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid.

(1*R*,2*S*,5*R*)-2-isopropyl-5-methylcyclohexyl *trans*-(1*R*,2*R*)-2-(3,4-difluorophenyl)-cyclopropanecarboxylate (9.6kg, 91.8% diastereomeric excess) was dissolved in ethanol (13.8kg) and heated with stirring to 46°C. 45% aqueous sodium hydroxide (3.1kg) was added over a 20 minute period and the mixture was stirred for a further 2 hours and 27 minutes. Solvent (28 L) was distilled out of the mixture under reduced pressure, then the mixture was cooled to 24°C and diluted with water (29.3kg), after which the liberated menthol was extracted into toluene (3 washes of 3.3kg each). The remaining aqueous material was acidified to pH 2 with 37% hydrochloric acid (3.3 L) and the product was extracted into toluene (8.6kg, then 2 more washes of 4.2kg and 4.3kg). The combined toluene extracts were washed with 1% hydrochloric acid (4.9 L), then diluted with further toluene (4.2kg) and azeotropically dried by distillation of the solvent (25 L) under reduced pressure. A final dilution with toluene (24.2kg) was followed by distillation of the solvent under reduced pressure (10 L) affording a solution containing *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid (approximately 3.45kg) suitable for the production of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride.

Step 8: Preparation of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride.

Pyridine (70ml) was added to a solution of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid (approximately 3.45kg) in toluene (approximately 12 -15kg), prepared as described above and the mixture was then heated to 65°C. Thionyl chloride (2.3kg) was added over a period of 1 hour and the mixture was

stirred at 70°C for 3 hours. Thionyl chloride (0.5kg) was added and the mixture was stirred a further 2 hours at 70°C. A final aliquot of thionyl chloride (0.5kg) was added and the reaction mixture was stirred for 1 hour at 70°C, then cooled to 40°C. Periodic additions of toluene (45kg, 3 additions of 15kg each) were made during distillation of solvent
5 (approximately 60 L) from the mixture under reduced pressure, then the solution of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride (approximately 3.8kg) in toluene (approximately 6-9 L) was cooled to 20°C.

Step 9: Preparation of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl azide.

10 A solution of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl chloride (approximately 3.8kg) in toluene (approximately 6-9 L), prepared in Step 8, at 1°C was added over a period of 74 minutes to a mixture of sodium azide (1.24kg), tetrabutylammonium bromide (56g) and sodium carbonate (922g) in water (6.2kg), stirring at 1.5°C. The mixture was stirred at 0°C for 1 hour and 55 minutes, then the aqueous layer
15 was diluted with cold water (3.8kg), stirred briefly, then separated. The toluene layer was washed once more at 0°C with water (3.8kg), then with 20% aqueous sodium chloride (3.8 L), then stored at 3°C for further use.

Step 10: Preparation of *trans*-(1*R*, 2*S*)-2-(3,4-difluorophenyl)cyclopropylamine.

20 A cold solution of *trans*-(1*R*, 2*R*)-2-(3,4-difluorophenyl)cyclopropanecarbonyl azide prepared as described in Step 9 was added over a period of 41 minutes to toluene (6.0kg) stirring at 100°C. The mixture was stirred for a further 55 minutes at 100°C, then cooled to 20°C and added over a period of 2 hours and 15 minutes to hydrochloric acid (3*M*, 18.2kg) stirring at 80°C. After 65 minutes the solution was diluted with water (34kg)
25 and cooled to 25°C. The toluene layer was removed and the aqueous layer was basified to pH 12 with 45% aqueous sodium hydroxide (3.8kg) and the product was then extracted into ethyl acetate (31kg) and washed twice with water (13.7kg per wash), affording a solution containing *trans*-(1*R*, 2*S*)-2-(3,4-difluorophenyl)cyclopropylamine (2.6kg, 91.8% enantiomeric excess) in ethyl acetate (29.5 L).

30


Step 11: Preparation of *trans*-(1*R*, 2*S*)-2-(3,4-difluorophenyl)cyclopropanaminium (2*R*)-2-hydroxy-2-phenylethanoate.

R-(-)-Mandelic acid (2.26kg) was added to a solution containing *trans*-(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropylamine (2.6kg, 91.8% enantiomeric excess), stirring at 17°C in ethyl acetate (45.3 L). The mixture was stirred at 25°C for 3 hours and 8 minutes, then filtered and washed twice with ethyl acetate (13.8kg total) The crystalline product was
5 dried at 40°C under reduced pressure for 23 hours, affording *trans*-(1*R*,2*S*)-2-(3,4-difluorophenyl)-cyclopropanaminium (2*R*)-2-hydroxy-2-phenylethanoate (4.45kg).

EXAMPLE 3


This Example illustrates the preparation of 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine.
10

Step 1: 4,6-Dihydroxy-2-(propylsulfanyl)pyrimidine.



Water (670ml) was added to 2-thiobarbituric acid (200 g). The resulting mixture was stirred and sodium hydroxide (126.3g) was added in portions. The mixture was stirred
15 for 40 min. then diluted with water. 1-Methyl-2-pyrrolidinone (400 ml) and 1-iodopropane (140.9ml) were then added. The resulting slurry was stirred at 20°C for 22h. The pH of the mixture was then adjusted to 6.5 by addition of 1M HCl (600ml) over 30 min, then to pH 2.5 by the addition of 6 M HCl (180ml) over a further 30 min. The resulting slurry was stirred for 18h and the product was isolated by filtration and washed successively with
20 water (4 X 100ml), ethanol (200ml) and water (2 X 200ml). The product was dried under reduced pressure overnight at 50°C to yield the title product as a white powder (185g).

Step 2: 4,6-Dihydroxy-5-[(*E*)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine.




Ethanol (25ml), 4,6-dihydroxy-2-(propylsulfanyl)pyrimidine (Step 1; 5g) and water (25 ml) were stirred together at room temperature. Sodium hydroxide (1.02g) was added and a clear solution obtained. The resulting solution was cooled to 0°C and then sodium acetate (9.42g) was added to give Solution A.

5 In a separate vessel, a solution of p-toluidine (3.01g) in water (10 ml) was prepared. To this was added concentrated hydrochloric acid (37% w/w aqueous solution; 8.45 ml). The resulting mixture was cooled to 0°C, and a solution of sodium nitrite (2.16g) in water (10ml) was cooled to 0°C and added dropwise to the toluidine – containing reaction mixture over 30 minutes. The temperature during the addition was kept between 0 and 5°C.
10 The resulting mixture was cooled to 0°C and added to the cold (0°C) Solution A (the temperature rose to 8°C). The resulting yellow suspension was stirred overnight and the pH of the mixture was adjusted to pH 1 by addition of 6 M HCl. The mixture was filtered and the collected product washed with water (25ml) ethanol (10ml). The product was dried under reduced pressure at 50°C over 24 h to give the product as a yellow solid (6.97g).


15

Step 3: 4,6-Dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine.



Pyridine (2.58ml) was added to a stirred, heated (70°C) slurry of 4,6-dihydroxy-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (Step 2, 5g) in toluene
20 (15ml). Phosphorous oxychloride (18.7ml) was added dropwise to the mixture over 15 min (exotherm to 94°C). The reaction mixture was heated for a further 4.5 h then evaporated. The residue was azeotroped twice with toluene (2 x 30ml). The residue was dissolved in toluene (50 ml) and filtered to remove some solids. The collected solid was washed with toluene and the combined filtrates washed with water (30ml) and saturated aqueous sodium
25 bicarbonate solution (30ml). Evaporation gave the title product (4.98g) as a red oil that slowly crystallised on standing.

Step 4: Preparation of 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine.



A stirred solution of 4,6-dichloro-5-[(E)-2-(4-methylphenyl)diazenyl]-2-(propylsulfanyl)pyrimidine (Step (3), 1.1kg) in 2-propanol (16.6kg) was hydrogenated for 1h at 40°C/3.2 bar over a platinum on carbon catalyst (0.81kg, 50% w/w Pt/C). The hydrogen gas pressure was released and the reactor flushed with nitrogen. The reaction mixture was filtered. The collected solid was washed with 2-propanol (1.7kg) and the combined filtrates were concentrated under reduced pressure. The residual oil was cooled to 20°C and dissolved in ethyl acetate (5kg) and water (5.5l) was added. The pH of the stirred mixture was adjusted to pH 2 by the addition of 3M aqueous hydrochloric acid (800ml). The phases were allowed to separate and the aqueous phase was discharged. Water (2.75l) was added to the organic phase and the pH was adjusted to 2 by the addition of a small amount of 3M HCl (45 ml). The aqueous phase was separated and the organic phase concentrated under reduced pressure at 30-50°C, to give 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine as a reddish viscous oil containing ethyl acetate that was dissolved in ethanol (8.5kg). Solvent (6.5l of ethanol/ethyl acetate) was then removed by distillation at reduced pressure. A further portion of ethanol (4.5kg) was added to the residue and the distillation repeated to remove 6.5 l of solvent. The ethanol solution of the product was used without further purification in the following step.


20

EXAMPLE 4

This Example illustrates the preparation of [1S-[1 α ,2 α ,3 β (1S*,2R*),5 β]]-3-[7-[2-(3,4-difluorophenyl)cyclopropyl-amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (alternatively named (1S,2S,3R,5S)-3-[7-
25 {[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol).

Step 1: Preparation of [3aR-(3 α ,4 α ,6 α ,6 α)]-2-[[6-[[5-amino-6-chloro-2-(propylthio)-4-pyrimidinyl]amino]tetrahydro-2,2-dimethyl-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]ethanol (alternatively named 2-[[[(3aR,4S,6R,6aS)-6-[[5-amino-6-chloro-2-


(propylsulfanyl)-4-pyrimidinyl]amino}-2,2-dimethyltetrahydro-3a*H*-cyclopenta[*d*][1,3]dioxol-4-yl]oxy]-1-ethanol).



The ethanolic solution of 4,6-dichloro-2-(propylsulfanyl)-5-pyrimidinamine,
 5 (prepared as in Example 3, Step 4) was added to 2-[[[(3a*R*,4*S*,6*R*,6a*S*)-6-amino-2,2-dimethyltetrahydro-3a*H*-cyclopenta[*d*][1,3]-dioxol-4-yl]oxy]-1-ethanol, L-tartaric acid salt (1:1) (1.18kg). To the resulting stirred thick slurry was charged triethylamine (0.95kg) maintaining the temperature between 20 and 25°C. The reactor was sealed and the temperature increased to 120-125°C. The reaction mixture was kept within this
 10 temperature range for 30h, then cooled to 75°C, and the pressure released. The temperature of the mixture was adjusted to 50°C and the solvent distilled off under reduced pressure at 30 to 40°C. Ethyl acetate (4.95kg) and water (5.5l) were added, the pH of the mixture adjusted to pH 5 by the addition of 3M hydrochloric acid (100 ml), and the phases were separated. The organic phase was washed with 15% w/w brine (5.5l), then separated. The
 15 organic phase was concentrated under reduced pressure (4.8l of solvent removed) to give 2-[[[(3a*R*,4*S*,6*R*,6a*S*)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3a*H*-cyclopenta[*d*][1,3]dioxol-4-yl]oxy]-1-ethanol as a brown-red viscous oil containing ethyl acetate. The product is used without further purification in the following step.


20 Step 2: Preparation of [3a*R*-(3aα,4α,6α,6aα)]-2-[[6-[7-chloro-5-(propylthio)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-3a*H*-cyclopenta[*d*][1,3]dioxol-4-yl]oxy]ethanol (alternatively named 2-[[[(3a*R*,4*S*,6*R*,6a*S*)-6-[7-chloro-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyltetrahydro-3a*H*-cyclopenta[*d*][1,3]dioxol-4-yl]oxy]-1-ethanol).
 25

16



2-[(3aR,4S,6R,6aS)-6-[[5-Amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl]amino]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy]-1-ethanol, as obtained in Step 1 was dissolved in acetic acid (5.75kg) and water (650ml). The resulting solution was cooled to 2°C (with stirring) and a solution of sodium nitrite (232g) in water (1.25l) was added such that the mixture temperature was held below 7°C. The mixture was then allowed to warm to 7°C then ethyl acetate (8.9kg) was added. Aqueous potassium carbonate solution (4l, 37%w/w) was added. The mixture was separated and the organic phase washed with further aqueous potassium carbonate solution (3.8kg, 21% w/w). The aqueous phase was discarded and the organic phase concentrated under reduced pressure to give the sub-titled compound as a red-brown viscous oil used without further purification in the following step.


Step 3: Preparation of {3aR-[3a α ,4 α ,6 α (1R*,2S*),6a α]}-2-[6-(7-[2-(3,4-difluorophenyl)cyclopropyl]amino)-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]tetrahydro-2,2-dimethyl-4H-cyclopenta-1,3-dioxol-4-yl]oxy]ethanol (alternatively named 2-[(3aR,4S,6R,6aS)-6-[7-[(1R,2S)-2-(3,4-difluorophenyl)-cyclopropyl]amino]-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl]oxy)-1-ethanol).



20

trans-(1*R*,2*S*)-2-(3,4-Difluorophenyl)cyclopropanaminium (2*R*)-2-hydroxy-2-phenylethanoate (0.77kg) was charged to a vessel followed by a solution of 2-((3*aR*,4*S*,6*R*,6*aS*)-6-[7-chloro-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyltetrahydro-3*aH*-cyclopenta-*d*[1,3]dioxol-4-yl}oxy)-1-ethanol (prepared as in Step 2) dissolved in acetonitrile (3.85kg). To the resulting stirred mixture was added triethylamine (0.81kg) at such a rate that the reaction temperature was maintained between 20-25°C. The reaction mixture was stirred for 13 h then concentrated at reduced pressure at 30°C. To the residue was added ethyl acetate (8.1kg) and water (4.6l). The pH of the stirred two phase mixture was adjusted to pH 4 by the addition of 3M HCl (450ml). The mixture was then allowed to settle and separate. The aqueous phase was separated and the retained organic phase was washed with 15% w/w aqueous sodium chloride solution (4.15kg), the organic phase was concentrated under reduced pressure at 30-50°C giving the crude title compound as a red oil, that was used directly in the next step.

Step 4: Preparation of [1*S*-[1 α ,2 α ,3 β (1*S**,2*R**),5 β]-3-[7-[2-(3,4-difluorophenyl)-cyclopropylamino]-5-(propylthio)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol (alternatively named (1*S*,2*S*,3*R*,5*S*)-3-[7-{{(1*R*,2*S*)-2-(3,4-Difluorophenyl)cyclopropyl}amino}-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol).



20

Aqueous hydrochloric acid (3 M, 4.8l), was added to a stirred solution of 2-((3*aR*,4*S*,6*R*,6*aS*)-6-[7-{{(1*R*,2*S*)-2-(3,4-difluorophenyl)cyclopropyl]-amino}-5-(propylsulfanyl)-3*H*-[1,2,3]triazolo[4,5-*d*]pyrimidin-3-yl]-2,2-dimethyltetrahydro-3*aH*-cyclopenta-*d*[1,3]dioxol-4-yl}oxy)-1-ethanol (1.931kg) in methanol (13.4kg), maintaining the temperature during the addition between 20 and 25°C. The mixture was then stirred for 24 h at 20°C. Sodium hydroxide (45% w/w aqueous solution; 780ml) was then added to adjust the pH of the mixture to pH 7.2. The methanol was then removed by distillation at

reduced pressure and ethyl acetate (14.3 kg) added. The mixture was heated to 45° and the aqueous layer separated. The organic phase was then washed 15% w/w aqueous sodium chloride solution (7.2kg). Ethyl acetate (10l) was removed by distillation at reduced pressure. Fresh ethyl acetate (7.2kg) was charged and the mixture filtered. The filter was washed with ethyl acetate (1.5kg). The combined filtrates were dried by repeated addition/distillation of ethyl acetate. When the solution was dry, the product content of the ethyl acetate solution was determined by a chromatographic assay technique and found to contain 1016g of product, the concentration of the ethyl acetate was adjusted until a concentration of 5ml ethyl acetate / g of the crude product was reached. The ethyl acetate solution was heated to 47°C and isooctane (2.5ml/g product, 2540ml) was then added over 15 min. The resulting slurry was stirred for 30 min. then more iso-octane (2540ml) was added over 5 mins. The resulting mixture was stirred at 48-50°C for 30 min then cooled to 20°C over 3h. The slurry was stirred at 20°C for 6.5 h then filtered and washed with a mixture consisting of iso-octane (1.25kg) and ethyl acetate (1.6kg). The collected solid was dried in vacuo to give the title compound (920g).

If desired, the crude product can be further purified by employing one of the following three methods.

Recrystallization from ethyl acetate / iso-octane

The crude product is dissolved in ethyl acetate (4.8 ml/g) at 55°C, then filtered to remove particles. The clear solution is taken back to the reactor for recrystallisation and the temperature is set at 50°C. iso-Octane is then added (4.8 ml/g) during 10 min. The slurry is allowed to stand for 30 minutes after which it is cooled to 20°C during 2-3 hours and finally the temperature is kept at 20°C for about 30 minutes. The product is then filtered and washed with iso-octane (2x1.5 ml/g). The product is dried under reduced pressure at 50°C giving pure product (>98% pure by h.p.l.c. analysis).

Slurry with n-butyl acetate

The crude product is suspended in n-butyl acetate 4 ml/g and stirred at room temperature for 10 hours. The slurry is cooled to 0°C during 3-4 hours and kept at 0°C for 1 hour. The product is filtered and washed with 2 ml/g of cold n-butyl acetate (<0°C). The


product is then dried in vacuo at 50°C, giving pure product (>98% pure by h.p.l.c. analysis).

Slurry with iso-propanol


- The crude product is suspended in iso-propanol 3 ml/g and stirred at 50°C for 72h.
- s The slurry is then cooled to 20°C during 3 hours and the temperature is kept at 20°C for about 30 minutes. The product is then filtered and washed with 1 ml/g of cold iso-propanol (<0°C). Finally, the product is dried under reduced pressure at 50°C giving pure product (>98% pure by h.p.l.c. analysis).

CLAIMS


1. A compound of formula (I):




2. A process for preparing a compound of formula (I), comprising reacting a compound of formula (II):



with a salt of a compound of formula (III):




3. A process for preparing a compound of formula (I) as claimed in claim 2 comprising hydrogenating a compound of formula (IV):




wherein Ar is phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy; to give a compound of formula (II), and reacting the compound of formula (II) with a compound of formula (III) to provide the compound of formula (I).

4. A process for preparing a compound of formula (II):




comprising hydrogenating a compound of formula (IV):




wherein Ar is phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy.

5. A process for preparing a compound of formula (II) as claimed in claim 2, comprising chlorinating a compound of formula (VIII):




wherein Ar is phenyl optionally substituted by halogen, C₁₋₄ alkyl or C₁₋₄ alkoxy, to provide a compound of formula (IV), and then hydrogenating the compound of formula (IV).

6. The use of a compound of formula (I) to prepare a compound of formula (A):




comprising:


- (a) reacting a compound of formula (I) with an alkali metal nitrite in the presence of a suitable acid to prepare a compound of formula (VII):



- (b) coupling the compound of formula (VII) with a compound of formula (VI):




to provide a compound of formula (V):



and,


- (c) deprotecting a compound of formula (V) to provide the compound of formula (A).

7. A process for preparing a salt of a compound of formula (III):




comprising reacting a compound of formula (III) with the necessary acid.

8. A process for preparing a salt of a compound of formula (III):




5 comprising the steps:

- (a) preparing a compound of formula (XI):




by reacting a compound of formula (XII):




10 with benzyl chloroformate;

- (b) preparing a compound of formula (X):




by reacting a compound of formula (XI) with a compound L-CH₂CO₂R*
{wherein R* is C₁₋₄ alkyl; and L is a leaving group};

- 15 (c) preparing a compound of formula (IX):



by reducing a compound of formula (X);

(d) preparing a compound of formula (III):



by deprotecting a compound of formula (IX); and,

(e) preparing a salt of a compound of formula (III) by reacting the compound of formula (III) with the necessary acid.

9. An intermediate compound of formula (II), (IV), (VII), (VIII), (X) or (XI) or a salt of a compound of formula (III).

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 01/01241

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 487/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 9941254 A1 (ASTRA PHARMACEUTICALS LTD.), 19 August 1999 (19.08.99), page 8; page 9 --	1,2,6,9
A	US 5905085 A (DAVID R. BORCHERDING ET AL), 18 May 1999 (18.05.99) --	1,2,6
A	WO 9101317 A1 (GLAXO GROUP LIMITED), 7 February 1991 (07.02.91) --	1,2,6
E,A	WO 0034283 A1 (ASTRAZENECA UK LIMITED), 15 June 2000 (15.06.00) -- -----	1,2,6,9

☐ Further documents are listed in the continuation of Box C.
 ☒ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

2 October 2001

Date of mailing of the international search report

04-10-2001

Name and mailing address of the ISA/

Swedish Patent Office

Box 5055, S-102 42 STOCKHOLM

Facsimile No. +46 8 666 02 86

Authorized officer

Fernando Farieta/EÖ

Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORT

Information on patent family members

03/09/01

International application No.

PCT/SE 01/01241

Patent document cited in search report			Publication date	Patent family member(s)		Publication date
WO	9941254	A1	19/08/99	AU	723699 B	07/09/00
				AU	2650099 A	30/08/99
				AU	6430498 A	12/10/98
				BR	9811253 A	26/09/00
				BR	9907934 A	24/10/00
				CN	1291193 T	11/04/01
				EP	1017439 A	12/07/00
				EP	1056749 A	06/12/00
				NO	994433 A	13/09/99
				NO	20004089 A	16/10/00
				PL	335701 A	08/05/00
				PL	342430 A	04/06/01
				SE	9800458 D	00/00/00
				SE	9803669 D	00/00/00
US	5905085	A	18/05/99	US	5723466 A	03/03/98
				US	5817660 A	06/10/98
				US	5817661 A	06/10/98
				US	5817672 A	06/10/98
				US	5916892 A	29/06/99
				US	5929079 A	27/07/99
				AT	194618 T	15/07/00
				AU	658698 B	27/04/95
				AU	2975292 A	10/06/93
				CA	2084222 A	07/06/93
				DE	69231242 D,T	21/12/00
				DK	545413 T	09/10/00
				EP	0545413 A,B	09/06/93
				SE	0545413 T3	
				ES	2149163 T	01/11/00
				FI	925520 A	07/06/93
				GR	3034586 T	31/01/01
				HU	217077 B	29/11/99
				HU	9203858 D	00/00/00
				IL	103962 A	10/01/97
				JP	6056835 A	01/03/94
				KR	251996 B	01/09/00
				MX	9206963 A	01/06/93
				NO	305207 B	19/04/99
				NO	924691 D	00/00/00
				NZ	245342 A	26/10/95
				PT	545413 T	31/10/00
				ZA	9209318 A	07/06/93
WO	9101317	A1	07/02/91	GB	8916477 D	00/00/00
WO	0034283	A1	15/06/00	AU	2016500 A	26/06/00
				NO	20012725 D	00/00/00
				SE	9804211 D	00/00/00
				AU	5077599 A	07/02/00
				BR	9912104 A	02/05/01
				EP	1097139 A	09/05/01
				NO	20010210 A	15/03/01
				SE	9901271 D	00/00/00

INTERNATIONAL SEARCH REPORT

International application No.
SE01/01241

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see next sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.: **1, 2, 6, 9**

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

According to Article 34(3) (a-c) and Rule 13.2, an international application shall relate to one invention only or to a group of inventions linked by one or more of the same or corresponding "special technical features", i. e. features, that define a contribution which each of the inventions makes over the prior art.

The problem the claimed invention aims to solve is a compound I : 2-[(3aR, 4S, 6R, 6aS)-6-[[5-amino-6-chloro-2-(propylsulfanyl)-4-pyrimidinyl] amino]-2,2 - dimethyltetrahydro-3aH-cyclopenta[d][1,3] oxy]-1-ethanol, a process for the preparation thereof and the use for the production of the compound (A). The process is performed in several steps where the essential step is the formation of a pyrimidinamine connected to a cyclopenta-dioxol (Claim 2) to form compound I (Claim 1).

Claims 3-9, which confers to process steps before the formation of compound I of claim 1, are formally associated with claim 1. However, the reaction described in claim 2 is not new and, as this step is to be considered as the unifying special technical feature, there is no such feature when the reaction of claim is known according to WO99/ 41254.

The reactions claimed in claims [3,7,8] and [4,5] are completely separated from the reaction described in claim 2. The application also contains a claim [9] concerning the intermediate and end products of the process. In order to fulfil the requirements of unity of invention it is necessary that the intermediate compounds are closely interconnected with the end products. Such close connection requires that the essential structural part of the end product is incorporated by the intermediate.

In the present invention the essential structural parts are a cyclopentanyl-amine directly attached to a pyrimidinamine. This structural parts are however not present in all the compounds claimed. Consequently the present application does not fulfil the requirements of unity of invention.

The application is found to contain the following three inventions:

Invention 1: Compounds I and VII, and a method for producing those compounds containing the same essential structural parts. As described in claims 1, 2, 6 and partly 9.

Invention 2: Compounds II, IV and VIII, and a method for producing those compounds. As described in claims 4, 5 and partly 9.

Invention 3: Compounds III, X and XI, and a method for producing those compounds. As described in claims 3, 7, 8 and partly 9.

As a consequence of the lack of unity of the application a complete search has not been performed. The search comprises only what is referred to as invention 1 above.